Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120 Heidelberg, Germany.
Mol Pharm. 2010 Dec 6;7(6):2224-31. doi: 10.1021/mp100223d. Epub 2010 Oct 7.
Cell-penetrating peptides (CPPs) are able to penetrate the cell membrane carrying cargoes such as peptides, proteins, oligonucleotides, siRNAs, radioisotopes, liposomes, and nanoparticles. Consequently, many delivery approaches have been developed to use CPPs as tools for drug delivery. However, until now a systematic analysis of their in vivo properties including potential tumor binding specificity for drug targeting purposes has not been conducted. Ten of the most commonly applied CPPs were obtained by solid phase peptide synthesis and labeled with (111)In or (68)Ga. Uptake studies were conducted using a panel of six tumor cell lines of different origin. The stability of the peptides was examined in human serum. Biodistribution experiments were conducted in nude mice bearing human prostate carcinoma. Finally, positron emission tomography (PET) measurements were performed in male Wistar rats. The in vitro uptake studies revealed high cellular uptake values, but no specificity toward any of the cell lines. The biodistribution in PC-3 tumor-bearing nude mice showed a high transient accumulation in well-perfused organs and a rapid clearance from the blood. All of the CPPs revealed a relatively low accumulation rate in the brain. The highest uptake values were observed in the liver (with a maximal uptake of 51 %ID/g observed for oligoarginine (R(9))) and the kidneys (with a maximal uptake of 94 %ID/g observed for NLS). The uptake values in the PC-3 tumor were low at all time points, indicating a lack of tumor specific accumulation for all peptides studied. A micro-PET imaging study with (68)Ga-labeled penetratin, Tat and transportan(10) (TP(10)) confirmed the organ distribution data. These data reveal that CPPs do not show evidence for application in tumor targeting purposes in vivo. However, CPPs readily penetrate into most organs and show rapid clearance from the circulation. The high uptake rates observed in vitro and the relatively low specificity in vivo imply that CPPs would be better suited for topical application in combination with cargoes which show passive targeting and dominate the pharmacokinetic behavior. In conclusion, CPPs are suitable as drug carriers for in vivo application provided that their pharmacokinetic properties are also considered in design of CPP drug delivery systems.
细胞穿透肽 (CPP) 能够穿透细胞膜携带货物,如肽、蛋白质、寡核苷酸、siRNA、放射性同位素、脂质体和纳米颗粒。因此,已经开发了许多递药方法来使用 CPP 作为递药工具。然而,到目前为止,还没有对其体内特性进行系统分析,包括用于药物靶向目的的潜在肿瘤结合特异性。通过固相肽合成获得了十种最常用的 CPP,并分别用 (111)In 或 (68)Ga 标记。使用一组六种不同来源的肿瘤细胞系进行摄取研究。在人血清中检查肽的稳定性。在荷有人前列腺癌的裸鼠中进行了生物分布实验。最后,在雄性 Wistar 大鼠中进行了正电子发射断层扫描 (PET) 测量。体外摄取研究显示出高细胞摄取值,但对任何细胞系都没有特异性。在荷 PC-3 肿瘤的裸鼠中的生物分布显示出在灌注良好的器官中高的短暂积累和从血液中快速清除。所有 CPP 在脑中的积累率都相对较低。在肝脏中观察到最高的摄取值(对于寡精氨酸 (R(9)),观察到最大摄取率为 51 %ID/g)和肾脏(对于 NLS,观察到最大摄取率为 94 %ID/g)。在所有时间点,PC-3 肿瘤中的摄取值都很低,表明所有研究的肽都没有肿瘤特异性积累。用 (68)Ga 标记的 penetratin、Tat 和 transportan(10)(TP(10))进行的 micro-PET 成像研究证实了器官分布数据。这些数据表明 CPP 没有证据表明在体内肿瘤靶向应用中有用。然而,CPP 很容易穿透大多数器官,并从循环中迅速清除。在体外观察到的高摄取率和体内相对较低的特异性表明,CPP 更适合与具有被动靶向并主导药代动力学行为的货物联合应用于局部应用。总之,只要 CPP 的药代动力学特性也在 CPP 药物传递系统的设计中得到考虑,它们就适合作为体内应用的药物载体。